» Articles » PMID: 38672496

Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Apr 27
PMID 38672496
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of glioma and the most common primary tumor of the central nervous system. Despite significant advances in clinical management strategies and diagnostic techniques for GBM in recent years, it remains a fatal disease. The current standard of care includes surgery, radiation, and chemotherapy, but the five-year survival rate for patients is less than 5%. The search for a more precise diagnosis and earlier intervention remains a critical and urgent challenge in clinical practice. The Notch signaling pathway is a critical signaling system that has been extensively studied in the malignant progression of glioblastoma. This highly conserved signaling cascade is central to a variety of biological processes, including growth, proliferation, self-renewal, migration, apoptosis, and metabolism. In GBM, accumulating data suggest that the Notch signaling pathway is hyperactive and contributes to GBM initiation, progression, and treatment resistance. This review summarizes the biological functions and molecular mechanisms of the Notch signaling pathway in GBM, as well as some clinical advances targeting the Notch signaling pathway in cancer and glioblastoma, highlighting its potential as a focus for novel therapeutic strategies.

Citing Articles

JAG1/Notch Pathway Inhibition Induces Ferroptosis and Promotes Cataractogenesis.

Ni Y, Liu L, Jiang F, Wu M, Qin Y Int J Mol Sci. 2025; 26(1.

PMID: 39796164 PMC: 11719987. DOI: 10.3390/ijms26010307.


Impact of Radiation on Invasion and Migration of Glioma In Vitro and In Vivo.

Santiago Franco M, Raulefs S, Schilling D, Combs S, Schmid T Cancers (Basel). 2024; 16(23).

PMID: 39682088 PMC: 11640451. DOI: 10.3390/cancers16233900.


Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Jin Y, Liu Q, Sun B, Li X, Wu J, Lin Z Discov Oncol. 2024; 15(1):709.

PMID: 39585461 PMC: 11589030. DOI: 10.1007/s12672-024-01572-2.


Genomic, epigenomic and transcriptomic landscape of glioblastoma.

Dakal T, Kakde G, Maurya P Metab Brain Dis. 2024; 39(8):1591-1611.

PMID: 39180605 DOI: 10.1007/s11011-024-01414-8.

References
1.
McBain C, Lawrie T, Rogozinska E, Kernohan A, Robinson T, Jefferies S . Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021; 5:CD013579. PMC: 8121043. DOI: 10.1002/14651858.CD013579.pub2. View

2.
Wong H, El Fatimy R, Onodera C, Wei Z, Yi M, Mohan A . The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Mol Ther. 2015; 23(7):1234-1247. PMC: 4817797. DOI: 10.1038/mt.2015.72. View

3.
Aithal M, Rajeswari N . Bacoside A Induced Sub-G0 Arrest and Early Apoptosis in Human Glioblastoma Cell Line U-87 MG through Notch Signaling Pathway. Brain Tumor Res Treat. 2019; 7(1):25-32. PMC: 6504756. DOI: 10.14791/btrt.2019.7.e21. View

4.
Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

5.
Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010; 12(11):1102-12. PMC: 3098027. DOI: 10.1093/neuonc/noq080. View